Baidu
map
J CLIN GASTROENTEROL 润色咨询

JOURNAL OF CLINICAL GASTROENTEROLOGY

出版年份：1979 年文章数：2971 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：1.9% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2221957, encodeId=de92222195e20, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：06/25/2024投稿<br>08/21/2024 Decision in Process<br>希望有好的结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edee8757188, createdName=ms6000001447507941, createdTime=Thu Aug 22 18:28:32 CST 2024, time=2024-08-22, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=557756, encodeId=76b455e756cf, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：WOS显示该杂志美国投稿占49%.其次是日本.中国投稿占1.4%.审稿快.编辑非常友好.仅供参考., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c52255767, createdName=12173988m66(暂无昵称), createdTime=Fri Jun 08 16:06:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124727, encodeId=96592124e273e, content=偏重的研究方向：消化病;胰腺<br>经验分享：是不是每个作者必须在邮箱确认，不确认是不是不进入审稿流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a4b8584778, createdName=ms7000000182828683, createdTime=Mon Apr 10 08:24:13 CST 2023, time=2023-04-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2097511, encodeId=ced4209e5116a, content=请问下这个期刊 为什么投稿3天了都没有收到编辑部发的确认投稿的PDF文件和链接呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=834a88316, createdName=luoxujuan, createdTime=Sun Oct 30 20:56:30 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242848, encodeId=cf8b124284860, content=偏重的研究方向：消化病;胃肠道<br>经验分享：请问一下这个刊，一般多久才分配稿件号啊？已经提交5天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:28:15 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242850, encodeId=984c124285078, content=偏重的研究方向：消化病;胃肠道<br>经验分享：投稿5天了 这个刊咋连稿件号都没有啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:29:35 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242927, encodeId=d6db124292e21, content=投稿命中率:50.0<br>偏重的研究方向：消化病;胃肠道<br>经验分享：这个期刊提交多少天后会分配稿件号啊？ 我提交都5天了😬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat Sep 03 10:36:15 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055265, encodeId=fae4105526533, content=7-12投稿<br>8-10送审<br>9-24状态显示decsion in process 至今<br>留个贴 期待给个修改。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94665282539, createdName=14847382m81(暂无昵称), createdTime=Mon Sep 27 09:29:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582493, encodeId=5cf5582493e1, content=可以<span class="quote">182SAV54960(暂无昵称) 2019-08-21 发表::<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span><span class="quote">cho1412 2019-08-21 10:05:00 发表:<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span>, beContent=182SAV54960(暂无昵称) 2019-08-21 发表:: 请问这个杂志可以接受共同第一作者吗，谢谢！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/22/a786206210efbc3d2f7165ec7ead6547.jpg, createdBy=d9ce2329140, createdName=huihui233, createdTime=Wed Jan 01 00:00:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092783, encodeId=02871092e83c7, content=每个期刊的格式要求一样么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2024-08-22 ms6000001447507941 来自福建省

    审稿速度:3.0 | 投稿命中率:25.0
    经验分享：06/25/2024投稿
    08/21/2024 Decision in Process
    希望有好的结果

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2221957, encodeId=de92222195e20, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：06/25/2024投稿<br>08/21/2024 Decision in Process<br>希望有好的结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edee8757188, createdName=ms6000001447507941, createdTime=Thu Aug 22 18:28:32 CST 2024, time=2024-08-22, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=557756, encodeId=76b455e756cf, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：WOS显示该杂志美国投稿占49%.其次是日本.中国投稿占1.4%.审稿快.编辑非常友好.仅供参考., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c52255767, createdName=12173988m66(暂无昵称), createdTime=Fri Jun 08 16:06:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124727, encodeId=96592124e273e, content=偏重的研究方向：消化病;胰腺<br>经验分享：是不是每个作者必须在邮箱确认，不确认是不是不进入审稿流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a4b8584778, createdName=ms7000000182828683, createdTime=Mon Apr 10 08:24:13 CST 2023, time=2023-04-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2097511, encodeId=ced4209e5116a, content=请问下这个期刊 为什么投稿3天了都没有收到编辑部发的确认投稿的PDF文件和链接呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=834a88316, createdName=luoxujuan, createdTime=Sun Oct 30 20:56:30 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242848, encodeId=cf8b124284860, content=偏重的研究方向：消化病;胃肠道<br>经验分享：请问一下这个刊，一般多久才分配稿件号啊？已经提交5天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:28:15 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242850, encodeId=984c124285078, content=偏重的研究方向：消化病;胃肠道<br>经验分享：投稿5天了 这个刊咋连稿件号都没有啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:29:35 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242927, encodeId=d6db124292e21, content=投稿命中率:50.0<br>偏重的研究方向：消化病;胃肠道<br>经验分享：这个期刊提交多少天后会分配稿件号啊？ 我提交都5天了😬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat Sep 03 10:36:15 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055265, encodeId=fae4105526533, content=7-12投稿<br>8-10送审<br>9-24状态显示decsion in process 至今<br>留个贴 期待给个修改。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94665282539, createdName=14847382m81(暂无昵称), createdTime=Mon Sep 27 09:29:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582493, encodeId=5cf5582493e1, content=可以<span class="quote">182SAV54960(暂无昵称) 2019-08-21 发表::<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span><span class="quote">cho1412 2019-08-21 10:05:00 发表:<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span>, beContent=182SAV54960(暂无昵称) 2019-08-21 发表:: 请问这个杂志可以接受共同第一作者吗，谢谢！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/22/a786206210efbc3d2f7165ec7ead6547.jpg, createdBy=d9ce2329140, createdName=huihui233, createdTime=Wed Jan 01 00:00:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092783, encodeId=02871092e83c7, content=每个期刊的格式要求一样么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2018-06-08 12173988m66(暂无昵称)

    审稿速度:1.0 | 投稿命中率:50.0
    经验分享：WOS显示该杂志美国投稿占49%.其次是日本.中国投稿占1.4%.审稿快.编辑非常友好.仅供参考.

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2221957, encodeId=de92222195e20, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：06/25/2024投稿<br>08/21/2024 Decision in Process<br>希望有好的结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edee8757188, createdName=ms6000001447507941, createdTime=Thu Aug 22 18:28:32 CST 2024, time=2024-08-22, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=557756, encodeId=76b455e756cf, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：WOS显示该杂志美国投稿占49%.其次是日本.中国投稿占1.4%.审稿快.编辑非常友好.仅供参考., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c52255767, createdName=12173988m66(暂无昵称), createdTime=Fri Jun 08 16:06:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124727, encodeId=96592124e273e, content=偏重的研究方向：消化病;胰腺<br>经验分享：是不是每个作者必须在邮箱确认，不确认是不是不进入审稿流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a4b8584778, createdName=ms7000000182828683, createdTime=Mon Apr 10 08:24:13 CST 2023, time=2023-04-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2097511, encodeId=ced4209e5116a, content=请问下这个期刊 为什么投稿3天了都没有收到编辑部发的确认投稿的PDF文件和链接呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=834a88316, createdName=luoxujuan, createdTime=Sun Oct 30 20:56:30 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242848, encodeId=cf8b124284860, content=偏重的研究方向：消化病;胃肠道<br>经验分享：请问一下这个刊，一般多久才分配稿件号啊？已经提交5天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:28:15 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242850, encodeId=984c124285078, content=偏重的研究方向：消化病;胃肠道<br>经验分享：投稿5天了 这个刊咋连稿件号都没有啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:29:35 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242927, encodeId=d6db124292e21, content=投稿命中率:50.0<br>偏重的研究方向：消化病;胃肠道<br>经验分享：这个期刊提交多少天后会分配稿件号啊？ 我提交都5天了😬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat Sep 03 10:36:15 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055265, encodeId=fae4105526533, content=7-12投稿<br>8-10送审<br>9-24状态显示decsion in process 至今<br>留个贴 期待给个修改。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94665282539, createdName=14847382m81(暂无昵称), createdTime=Mon Sep 27 09:29:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582493, encodeId=5cf5582493e1, content=可以<span class="quote">182SAV54960(暂无昵称) 2019-08-21 发表::<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span><span class="quote">cho1412 2019-08-21 10:05:00 发表:<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span>, beContent=182SAV54960(暂无昵称) 2019-08-21 发表:: 请问这个杂志可以接受共同第一作者吗，谢谢！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/22/a786206210efbc3d2f7165ec7ead6547.jpg, createdBy=d9ce2329140, createdName=huihui233, createdTime=Wed Jan 01 00:00:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092783, encodeId=02871092e83c7, content=每个期刊的格式要求一样么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2023-04-10 ms7000000182828683 来自四川省

    偏重的研究方向：消化病;胰腺
    经验分享：是不是每个作者必须在邮箱确认，不确认是不是不进入审稿流程？

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2221957, encodeId=de92222195e20, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：06/25/2024投稿<br>08/21/2024 Decision in Process<br>希望有好的结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edee8757188, createdName=ms6000001447507941, createdTime=Thu Aug 22 18:28:32 CST 2024, time=2024-08-22, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=557756, encodeId=76b455e756cf, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：WOS显示该杂志美国投稿占49%.其次是日本.中国投稿占1.4%.审稿快.编辑非常友好.仅供参考., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c52255767, createdName=12173988m66(暂无昵称), createdTime=Fri Jun 08 16:06:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124727, encodeId=96592124e273e, content=偏重的研究方向：消化病;胰腺<br>经验分享：是不是每个作者必须在邮箱确认，不确认是不是不进入审稿流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a4b8584778, createdName=ms7000000182828683, createdTime=Mon Apr 10 08:24:13 CST 2023, time=2023-04-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2097511, encodeId=ced4209e5116a, content=请问下这个期刊 为什么投稿3天了都没有收到编辑部发的确认投稿的PDF文件和链接呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=834a88316, createdName=luoxujuan, createdTime=Sun Oct 30 20:56:30 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242848, encodeId=cf8b124284860, content=偏重的研究方向：消化病;胃肠道<br>经验分享：请问一下这个刊，一般多久才分配稿件号啊？已经提交5天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:28:15 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242850, encodeId=984c124285078, content=偏重的研究方向：消化病;胃肠道<br>经验分享：投稿5天了 这个刊咋连稿件号都没有啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:29:35 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242927, encodeId=d6db124292e21, content=投稿命中率:50.0<br>偏重的研究方向：消化病;胃肠道<br>经验分享：这个期刊提交多少天后会分配稿件号啊？ 我提交都5天了😬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat Sep 03 10:36:15 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055265, encodeId=fae4105526533, content=7-12投稿<br>8-10送审<br>9-24状态显示decsion in process 至今<br>留个贴 期待给个修改。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94665282539, createdName=14847382m81(暂无昵称), createdTime=Mon Sep 27 09:29:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582493, encodeId=5cf5582493e1, content=可以<span class="quote">182SAV54960(暂无昵称) 2019-08-21 发表::<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span><span class="quote">cho1412 2019-08-21 10:05:00 发表:<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span>, beContent=182SAV54960(暂无昵称) 2019-08-21 发表:: 请问这个杂志可以接受共同第一作者吗，谢谢！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/22/a786206210efbc3d2f7165ec7ead6547.jpg, createdBy=d9ce2329140, createdName=huihui233, createdTime=Wed Jan 01 00:00:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092783, encodeId=02871092e83c7, content=每个期刊的格式要求一样么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2022-10-30 luoxujuan

    请问下这个期刊 为什么投稿3天了都没有收到编辑部发的确认投稿的PDF文件和链接呢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2221957, encodeId=de92222195e20, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：06/25/2024投稿<br>08/21/2024 Decision in Process<br>希望有好的结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edee8757188, createdName=ms6000001447507941, createdTime=Thu Aug 22 18:28:32 CST 2024, time=2024-08-22, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=557756, encodeId=76b455e756cf, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：WOS显示该杂志美国投稿占49%.其次是日本.中国投稿占1.4%.审稿快.编辑非常友好.仅供参考., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c52255767, createdName=12173988m66(暂无昵称), createdTime=Fri Jun 08 16:06:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124727, encodeId=96592124e273e, content=偏重的研究方向：消化病;胰腺<br>经验分享：是不是每个作者必须在邮箱确认，不确认是不是不进入审稿流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a4b8584778, createdName=ms7000000182828683, createdTime=Mon Apr 10 08:24:13 CST 2023, time=2023-04-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2097511, encodeId=ced4209e5116a, content=请问下这个期刊 为什么投稿3天了都没有收到编辑部发的确认投稿的PDF文件和链接呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=834a88316, createdName=luoxujuan, createdTime=Sun Oct 30 20:56:30 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242848, encodeId=cf8b124284860, content=偏重的研究方向：消化病;胃肠道<br>经验分享：请问一下这个刊，一般多久才分配稿件号啊？已经提交5天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:28:15 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242850, encodeId=984c124285078, content=偏重的研究方向：消化病;胃肠道<br>经验分享：投稿5天了 这个刊咋连稿件号都没有啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:29:35 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242927, encodeId=d6db124292e21, content=投稿命中率:50.0<br>偏重的研究方向：消化病;胃肠道<br>经验分享：这个期刊提交多少天后会分配稿件号啊？ 我提交都5天了😬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat Sep 03 10:36:15 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055265, encodeId=fae4105526533, content=7-12投稿<br>8-10送审<br>9-24状态显示decsion in process 至今<br>留个贴 期待给个修改。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94665282539, createdName=14847382m81(暂无昵称), createdTime=Mon Sep 27 09:29:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582493, encodeId=5cf5582493e1, content=可以<span class="quote">182SAV54960(暂无昵称) 2019-08-21 发表::<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span><span class="quote">cho1412 2019-08-21 10:05:00 发表:<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span>, beContent=182SAV54960(暂无昵称) 2019-08-21 发表:: 请问这个杂志可以接受共同第一作者吗，谢谢！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/22/a786206210efbc3d2f7165ec7ead6547.jpg, createdBy=d9ce2329140, createdName=huihui233, createdTime=Wed Jan 01 00:00:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092783, encodeId=02871092e83c7, content=每个期刊的格式要求一样么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2022-09-02 ms1000000867109818

    偏重的研究方向：消化病;胃肠道
    经验分享：请问一下这个刊，一般多久才分配稿件号啊？已经提交5天了。

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2221957, encodeId=de92222195e20, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：06/25/2024投稿<br>08/21/2024 Decision in Process<br>希望有好的结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edee8757188, createdName=ms6000001447507941, createdTime=Thu Aug 22 18:28:32 CST 2024, time=2024-08-22, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=557756, encodeId=76b455e756cf, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：WOS显示该杂志美国投稿占49%.其次是日本.中国投稿占1.4%.审稿快.编辑非常友好.仅供参考., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c52255767, createdName=12173988m66(暂无昵称), createdTime=Fri Jun 08 16:06:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124727, encodeId=96592124e273e, content=偏重的研究方向：消化病;胰腺<br>经验分享：是不是每个作者必须在邮箱确认，不确认是不是不进入审稿流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a4b8584778, createdName=ms7000000182828683, createdTime=Mon Apr 10 08:24:13 CST 2023, time=2023-04-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2097511, encodeId=ced4209e5116a, content=请问下这个期刊 为什么投稿3天了都没有收到编辑部发的确认投稿的PDF文件和链接呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=834a88316, createdName=luoxujuan, createdTime=Sun Oct 30 20:56:30 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242848, encodeId=cf8b124284860, content=偏重的研究方向：消化病;胃肠道<br>经验分享：请问一下这个刊，一般多久才分配稿件号啊？已经提交5天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:28:15 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242850, encodeId=984c124285078, content=偏重的研究方向：消化病;胃肠道<br>经验分享：投稿5天了 这个刊咋连稿件号都没有啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:29:35 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242927, encodeId=d6db124292e21, content=投稿命中率:50.0<br>偏重的研究方向：消化病;胃肠道<br>经验分享：这个期刊提交多少天后会分配稿件号啊？ 我提交都5天了😬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat Sep 03 10:36:15 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055265, encodeId=fae4105526533, content=7-12投稿<br>8-10送审<br>9-24状态显示decsion in process 至今<br>留个贴 期待给个修改。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94665282539, createdName=14847382m81(暂无昵称), createdTime=Mon Sep 27 09:29:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582493, encodeId=5cf5582493e1, content=可以<span class="quote">182SAV54960(暂无昵称) 2019-08-21 发表::<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span><span class="quote">cho1412 2019-08-21 10:05:00 发表:<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span>, beContent=182SAV54960(暂无昵称) 2019-08-21 发表:: 请问这个杂志可以接受共同第一作者吗，谢谢！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/22/a786206210efbc3d2f7165ec7ead6547.jpg, createdBy=d9ce2329140, createdName=huihui233, createdTime=Wed Jan 01 00:00:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092783, encodeId=02871092e83c7, content=每个期刊的格式要求一样么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2022-09-02 ms1000000867109818

    偏重的研究方向：消化病;胃肠道
    经验分享：投稿5天了 这个刊咋连稿件号都没有啊

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2221957, encodeId=de92222195e20, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：06/25/2024投稿<br>08/21/2024 Decision in Process<br>希望有好的结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edee8757188, createdName=ms6000001447507941, createdTime=Thu Aug 22 18:28:32 CST 2024, time=2024-08-22, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=557756, encodeId=76b455e756cf, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：WOS显示该杂志美国投稿占49%.其次是日本.中国投稿占1.4%.审稿快.编辑非常友好.仅供参考., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c52255767, createdName=12173988m66(暂无昵称), createdTime=Fri Jun 08 16:06:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124727, encodeId=96592124e273e, content=偏重的研究方向：消化病;胰腺<br>经验分享：是不是每个作者必须在邮箱确认，不确认是不是不进入审稿流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a4b8584778, createdName=ms7000000182828683, createdTime=Mon Apr 10 08:24:13 CST 2023, time=2023-04-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2097511, encodeId=ced4209e5116a, content=请问下这个期刊 为什么投稿3天了都没有收到编辑部发的确认投稿的PDF文件和链接呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=834a88316, createdName=luoxujuan, createdTime=Sun Oct 30 20:56:30 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242848, encodeId=cf8b124284860, content=偏重的研究方向：消化病;胃肠道<br>经验分享：请问一下这个刊，一般多久才分配稿件号啊？已经提交5天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:28:15 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242850, encodeId=984c124285078, content=偏重的研究方向：消化病;胃肠道<br>经验分享：投稿5天了 这个刊咋连稿件号都没有啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:29:35 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242927, encodeId=d6db124292e21, content=投稿命中率:50.0<br>偏重的研究方向：消化病;胃肠道<br>经验分享：这个期刊提交多少天后会分配稿件号啊？ 我提交都5天了😬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat Sep 03 10:36:15 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055265, encodeId=fae4105526533, content=7-12投稿<br>8-10送审<br>9-24状态显示decsion in process 至今<br>留个贴 期待给个修改。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94665282539, createdName=14847382m81(暂无昵称), createdTime=Mon Sep 27 09:29:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582493, encodeId=5cf5582493e1, content=可以<span class="quote">182SAV54960(暂无昵称) 2019-08-21 发表::<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span><span class="quote">cho1412 2019-08-21 10:05:00 发表:<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span>, beContent=182SAV54960(暂无昵称) 2019-08-21 发表:: 请问这个杂志可以接受共同第一作者吗，谢谢！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/22/a786206210efbc3d2f7165ec7ead6547.jpg, createdBy=d9ce2329140, createdName=huihui233, createdTime=Wed Jan 01 00:00:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092783, encodeId=02871092e83c7, content=每个期刊的格式要求一样么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2022-09-03 ms1000000867109818

    投稿命中率:50.0
    偏重的研究方向：消化病;胃肠道
    经验分享：这个期刊提交多少天后会分配稿件号啊？ 我提交都5天了😬

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2221957, encodeId=de92222195e20, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：06/25/2024投稿<br>08/21/2024 Decision in Process<br>希望有好的结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edee8757188, createdName=ms6000001447507941, createdTime=Thu Aug 22 18:28:32 CST 2024, time=2024-08-22, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=557756, encodeId=76b455e756cf, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：WOS显示该杂志美国投稿占49%.其次是日本.中国投稿占1.4%.审稿快.编辑非常友好.仅供参考., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c52255767, createdName=12173988m66(暂无昵称), createdTime=Fri Jun 08 16:06:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124727, encodeId=96592124e273e, content=偏重的研究方向：消化病;胰腺<br>经验分享：是不是每个作者必须在邮箱确认，不确认是不是不进入审稿流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a4b8584778, createdName=ms7000000182828683, createdTime=Mon Apr 10 08:24:13 CST 2023, time=2023-04-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2097511, encodeId=ced4209e5116a, content=请问下这个期刊 为什么投稿3天了都没有收到编辑部发的确认投稿的PDF文件和链接呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=834a88316, createdName=luoxujuan, createdTime=Sun Oct 30 20:56:30 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242848, encodeId=cf8b124284860, content=偏重的研究方向：消化病;胃肠道<br>经验分享：请问一下这个刊，一般多久才分配稿件号啊？已经提交5天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:28:15 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242850, encodeId=984c124285078, content=偏重的研究方向：消化病;胃肠道<br>经验分享：投稿5天了 这个刊咋连稿件号都没有啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:29:35 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242927, encodeId=d6db124292e21, content=投稿命中率:50.0<br>偏重的研究方向：消化病;胃肠道<br>经验分享：这个期刊提交多少天后会分配稿件号啊？ 我提交都5天了😬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat Sep 03 10:36:15 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055265, encodeId=fae4105526533, content=7-12投稿<br>8-10送审<br>9-24状态显示decsion in process 至今<br>留个贴 期待给个修改。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94665282539, createdName=14847382m81(暂无昵称), createdTime=Mon Sep 27 09:29:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582493, encodeId=5cf5582493e1, content=可以<span class="quote">182SAV54960(暂无昵称) 2019-08-21 发表::<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span><span class="quote">cho1412 2019-08-21 10:05:00 发表:<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span>, beContent=182SAV54960(暂无昵称) 2019-08-21 发表:: 请问这个杂志可以接受共同第一作者吗，谢谢！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/22/a786206210efbc3d2f7165ec7ead6547.jpg, createdBy=d9ce2329140, createdName=huihui233, createdTime=Wed Jan 01 00:00:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092783, encodeId=02871092e83c7, content=每个期刊的格式要求一样么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2021-09-27 14847382m81(暂无昵称)

    7-12投稿
    8-10送审
    9-24状态显示decsion in process 至今
    留个贴 期待给个修改。。。。。

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2221957, encodeId=de92222195e20, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：06/25/2024投稿<br>08/21/2024 Decision in Process<br>希望有好的结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edee8757188, createdName=ms6000001447507941, createdTime=Thu Aug 22 18:28:32 CST 2024, time=2024-08-22, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=557756, encodeId=76b455e756cf, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：WOS显示该杂志美国投稿占49%.其次是日本.中国投稿占1.4%.审稿快.编辑非常友好.仅供参考., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c52255767, createdName=12173988m66(暂无昵称), createdTime=Fri Jun 08 16:06:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124727, encodeId=96592124e273e, content=偏重的研究方向：消化病;胰腺<br>经验分享：是不是每个作者必须在邮箱确认，不确认是不是不进入审稿流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a4b8584778, createdName=ms7000000182828683, createdTime=Mon Apr 10 08:24:13 CST 2023, time=2023-04-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2097511, encodeId=ced4209e5116a, content=请问下这个期刊 为什么投稿3天了都没有收到编辑部发的确认投稿的PDF文件和链接呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=834a88316, createdName=luoxujuan, createdTime=Sun Oct 30 20:56:30 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242848, encodeId=cf8b124284860, content=偏重的研究方向：消化病;胃肠道<br>经验分享：请问一下这个刊，一般多久才分配稿件号啊？已经提交5天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:28:15 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242850, encodeId=984c124285078, content=偏重的研究方向：消化病;胃肠道<br>经验分享：投稿5天了 这个刊咋连稿件号都没有啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:29:35 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242927, encodeId=d6db124292e21, content=投稿命中率:50.0<br>偏重的研究方向：消化病;胃肠道<br>经验分享：这个期刊提交多少天后会分配稿件号啊？ 我提交都5天了😬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat Sep 03 10:36:15 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055265, encodeId=fae4105526533, content=7-12投稿<br>8-10送审<br>9-24状态显示decsion in process 至今<br>留个贴 期待给个修改。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94665282539, createdName=14847382m81(暂无昵称), createdTime=Mon Sep 27 09:29:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582493, encodeId=5cf5582493e1, content=可以<span class="quote">182SAV54960(暂无昵称) 2019-08-21 发表::<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span><span class="quote">cho1412 2019-08-21 10:05:00 发表:<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span>, beContent=182SAV54960(暂无昵称) 2019-08-21 发表:: 请问这个杂志可以接受共同第一作者吗，谢谢！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/22/a786206210efbc3d2f7165ec7ead6547.jpg, createdBy=d9ce2329140, createdName=huihui233, createdTime=Wed Jan 01 00:00:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092783, encodeId=02871092e83c7, content=每个期刊的格式要求一样么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2020-01-01 huihui233

    可以182SAV54960(暂无昵称) 2019-08-21 发表::
    请问这个杂志可以接受共同第一作者吗，谢谢！    cho1412 2019-08-21 10:05:00 发表:
    请问这个杂志可以接受共同第一作者吗，谢谢！

    182SAV54960(暂无昵称) 2019-08-21 发表:: 请问这个杂志可以接受共同第一作者吗，谢谢！

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2221957, encodeId=de92222195e20, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：06/25/2024投稿<br>08/21/2024 Decision in Process<br>希望有好的结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edee8757188, createdName=ms6000001447507941, createdTime=Thu Aug 22 18:28:32 CST 2024, time=2024-08-22, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=557756, encodeId=76b455e756cf, content=审稿速度:1.0 | 投稿命中率:50.0<br>经验分享：WOS显示该杂志美国投稿占49%.其次是日本.中国投稿占1.4%.审稿快.编辑非常友好.仅供参考., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c52255767, createdName=12173988m66(暂无昵称), createdTime=Fri Jun 08 16:06:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2124727, encodeId=96592124e273e, content=偏重的研究方向：消化病;胰腺<br>经验分享：是不是每个作者必须在邮箱确认，不确认是不是不进入审稿流程？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a4b8584778, createdName=ms7000000182828683, createdTime=Mon Apr 10 08:24:13 CST 2023, time=2023-04-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2097511, encodeId=ced4209e5116a, content=请问下这个期刊 为什么投稿3天了都没有收到编辑部发的确认投稿的PDF文件和链接呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=834a88316, createdName=luoxujuan, createdTime=Sun Oct 30 20:56:30 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242848, encodeId=cf8b124284860, content=偏重的研究方向：消化病;胃肠道<br>经验分享：请问一下这个刊，一般多久才分配稿件号啊？已经提交5天了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:28:15 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242850, encodeId=984c124285078, content=偏重的研究方向：消化病;胃肠道<br>经验分享：投稿5天了 这个刊咋连稿件号都没有啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Fri Sep 02 19:29:35 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242927, encodeId=d6db124292e21, content=投稿命中率:50.0<br>偏重的研究方向：消化病;胃肠道<br>经验分享：这个期刊提交多少天后会分配稿件号啊？ 我提交都5天了😬, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efce6162787, createdName=ms1000000867109818, createdTime=Sat Sep 03 10:36:15 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055265, encodeId=fae4105526533, content=7-12投稿<br>8-10送审<br>9-24状态显示decsion in process 至今<br>留个贴 期待给个修改。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94665282539, createdName=14847382m81(暂无昵称), createdTime=Mon Sep 27 09:29:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582493, encodeId=5cf5582493e1, content=可以<span class="quote">182SAV54960(暂无昵称) 2019-08-21 发表::<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span><span class="quote">cho1412 2019-08-21 10:05:00 发表:<br>请问这个杂志可以接受共同第一作者吗，谢谢！</span>, beContent=182SAV54960(暂无昵称) 2019-08-21 发表:: 请问这个杂志可以接受共同第一作者吗，谢谢！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/22/a786206210efbc3d2f7165ec7ead6547.jpg, createdBy=d9ce2329140, createdName=huihui233, createdTime=Wed Jan 01 00:00:00 CST 2020, time=2020-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092783, encodeId=02871092e83c7, content=每个期刊的格式要求一样么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2021-12-29 rayms

    每个期刊的格式要求一样么？

    1

    展开1条回复
共60条页码: 1/6页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map